Video Experimental Relacionado

Updated: Feb 19, 2026

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay

Published on: December 19, 2018

Inducción Alostérica de la Tetramerización del Dominio de Unión al Ligando del Receptor de Estrógenos por un

Emma C Fink¹, Reena Chawla², Govinda R Hancock¹

¹Department of Cancer Biology, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois 60546, United States.

ACS medicinal chemistry letters

|February 18, 2026

Resumen

Nueva investigación presenta OP-1690, un novedoso antagonista completo del receptor de estrógenos (CERAN) para el cáncer de mama ER+. Este compuesto forma de manera única tetrámeros de ERα, ofreciendo nuevas vías terapéuticas más allá de los tratamientos convencionales.

Área de la Ciencia:

Oncología
Endocrinología
Química Medicinal

Sus antecedentes:

Los antagonistas completos del receptor de estrógenos (CERAN) son vitales para el tratamiento de los cánceres de mama avanzados con receptores de estrógenos positivos (ER+).
Los andamios químicos CERAN existentes restringen la exploración de la farmacología del receptor de estrógenos (ER).

Objetivo del estudio:

Sintetizar y caracterizar un CERAN novedoso con un núcleo distinto y sin restricciones.
Investigar el mecanismo de acción único del nuevo compuesto, OP-1690.

Principales métodos:

Síntesis de OP-1690 (compuesto 2).
Análisis estructurales y biofísicos para determinar las interacciones del receptor.
Evaluación de la formación del dominio de unión al ligando (LBD) del receptor de estrógenos alfa (ERα).

Principales resultados:

Se sintetizó con éxito OP-1690 (compuesto 2), que presenta un núcleo novedoso y sin restricciones.
El compuesto 2 induce de forma única la formación de tetrámeros de ERα LBD.
Esta formación de tetrámeros representa un mecanismo más allá de la homodimerización convencional de ERα.

Conclusiones:

Los andamios CERAN novedosos, como OP-1690, pueden descubrir mecanismos de acción de ER previamente no reconocidos.
La capacidad de OP-1690 para promover la formación de tetrámeros de ERα ofrece nuevas perspectivas sobre la farmacología de ER.
Este descubrimiento puede conducir a estrategias terapéuticas mejoradas para los cánceres de mama ER+.

Palabras clave:

CERAN Receptor nuclear Receptor de estrógenos Hormona No esteroideo Oligomerización

Más Videos Relacionados

Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines

Dissection of Enhancer Function Using Multiplex CRISPR-based Enhancer Interference in Cell Lines

Published on: June 2, 2018

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Screening for Phytoestrogens using a Cell-based Estrogen Receptor β Reporter Assay

Published on: June 7, 2020

Videos de Conceptos Relacionados

The Two-State Receptor Model

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...

Drug-Receptor Interaction: Antagonist

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...

Drug-Receptor Interactions

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....

Cooperative Allosteric Transitions

Cooperative Allosteric Transitions

Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...

Cooperative Allosteric Transitions

Cooperative Allosteric Transitions

Drug-Receptor Interaction: Agonist

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...